Phase II Study of Weekly Paclitaxel as a Second-line Treatment for S-1-refractory Advanced Gastric Cancer

• Published in: Anticancer research Vol. 29; no. 7; pp. 2863 - 2867
• Main Authors: MATSUDA, Goro, KUNISAKI, Chikara, KOSAKA, Takashi, ONO, Hedetaka A, AKIYAMA, Hirotoshi, ICHIKAWA, Yasushi, MAKINO, Hirochika, FUKAHORI, Michiko, KIMURA, Jun, SATO, Tsutomu, OSHIMA, Takashi, NAGANO, Yasuhiko, FUII, Shoichi, TAKAGAWA, Ryo
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.07.2009
• Subjects: Aged; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Biological and medical sciences; Drug Administration Schedule; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Male; Medical sciences; Middle Aged; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Paclitaxel - therapeutic use; Stomach Neoplasms - drug therapy; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors; Antineoplastic agent; second-line treatment; Treatment resistance; Malignant tumor; Stomach cancer; Advanced gastric cancer; Cancerology; Taxane derivatives; S-1; Phase II trial; Paclitaxel; Digestive diseases; Advanced stage; Second line treatment; Antimitotic; Cancer; Gastric disease
• ISSN: 0250-7005; 1791-7530

Background: We retrospectively evaluated the efficacy of weekly paclitaxel therapy as second-line treatment for patients with advanced gastric cancer that was refractory to S-1. Patients and Methods: In total, 33 patients received intravenous paclitaxel (80 mg m -2 ) on days 1, 8 and 15 as part of a 4-week cycle. Results: Eight patients showed a partial response, 11 showed stable disease and 14 showed disease progression. In total, 171 courses (mean=5.2; range=3-16) were administered. Thirteen cases subsequently underwent third-line treatment. The median survival time and time to progression from the time of second-line treatment was 8.0 months and 4.2 months, respectively. The most common haematological toxicities were leukopenia and neutropenia. Non-haematological toxicities were generally mild to moderate and controllable. Conclusion: This study showed favourable therapeutic outcomes for advanced gastric cancer patients. However, it will be necessary to confirm the advantages of paclitaxel treatment for S-1-refractory advanced gastric cancer in a larger population.